Updated Interim Clinical Considerations for Use of COVID Vaccines

Having trouble viewing this email? View it as a Web page.

Bookmark and Share

Updated Interim Clinical Considerations for Use of COVID Vaccines

March 30, 2022

Today, CDC updated the Interim Clinical Considerations for Use of COVID Vaccines in the United States to include guidance that says individuals 12 years and older who are moderately or severely immunocompromised and adults 50 years and older who are not moderately or severely immunocompromised “may choose to receive” a second mRNA booster 4 months after their first booster dose. 

The updated guidance also states that people 18-49 who are not moderately or severely immunocompromised who received the Janssen vaccine for both primary and booster doses “may receive” a second mRNA booster dose 4 months after the first Janssen booster. Please see below for a summary of all the updates in the clinical considerations:  

  • Added guidance that people ages 12 years and older who are moderately or severely immunocompromised may choose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster dose 
  • Added guidance that adults ages 50 years and older who are not moderately or severely immunocompromised may choose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster dose 
  • Added guidance that people ages 18–49 years who are not moderately or severely immunocompromised and who received Janssen COVID-19 Vaccine as both their primary series dose and booster dose may receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first Janssen booster dose 
  • Further clarification of safety issues including those related to multisystem inflammatory syndrome in children (MIS-C) and adults (MIS-A) and myocarditis 
  • Updated information on the availability of Moderna COVID-19 Vaccine supplied in a vial with a red cap (0.25 mL dosage volume) and Moderna COVID-19 Vaccine supplied in a vial with a blue cap (0.5 mL dosage volume) for administration of a 50 µg booster dose.